← Back to Search

Participants with stage I-IV colorectal cancer (CRC) for Colorectal Cancer

N/A
Recruiting
Led By Kristiyana Kaneva, MD, MS
Research Sponsored by Tempus AI
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Eligible Conditions
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence-Free Survival
Secondary outcome measures
Positive Predictive Value
Sensitivity
Specificity
Other outcome measures
Lead Time
Overall Survival

Side effects data

From 2016 Phase 3 trial • 356 Patients • NCT00048997
31%
Fatigue (lethargy, malaise, asthenia)
23%
Alopecia
17%
Late RT Toxicity: Other: NOS
11%
Nausea
10%
Anorexia
9%
Late RT Toxicity: Brain: NOS
9%
Headache
7%
Late RT Toxicity: Skin: NOS
6%
Memory loss
1%
Dyspnea (shortness of breath)
1%
Hemorrhage-Other
1%
Ataxia (incoordination)
1%
Mood alteration-depression
1%
Pain-Other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Prophylactic Cranial Irradiation (PCI)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with stage I-IV colorectal cancer (CRC)Experimental Treatment1 Intervention
This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.

Find a Location

Who is running the clinical trial?

Tempus AILead Sponsor
16 Previous Clinical Trials
17,744 Total Patients Enrolled
Tempus LabsLead Sponsor
16 Previous Clinical Trials
18,244 Total Patients Enrolled
Kristiyana Kaneva, MD, MSPrincipal InvestigatorTempus AI, Inc.
1 Previous Clinical Trials
1,200 Total Patients Enrolled
~21 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top